1. Pink Sheet
  2. >>Legal & IP

Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit

 
• By Michael McCaughan

Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.

Businessman with drawn cape on white brick background. Leadership concept
Is Allergan a hero or a villian?

A year ago, Allergan PLC staked out an unlikely position as a leader in corporate responsibility, announcing a “social contract” that included the first formal pledge by a leading biopharma company to restrain price increases in response to headlines and hearings criticizing “outrageous” pricing for older brands.

At the same time, Allergan embraces a new identity as a “bold” company, changing its boilerplate language in press releases to say: “Allergan plc, headquartered in Dublin, Ireland, is a bold, global

More from Legal & IP

More from Pink Sheet

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.